Digital Content 
NEWS #PharmaBuzz
14 Oct 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/caristo-chosen-by-leading-pharma-company-as-worldwide-imaging-core-lab-to-measure-coronary-plaque-and-inflammation-302583106.html
02 Sep 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/menarini-groups-obicetrapib-and-obicetrapibezetimibe-marketing-authorisation-applications-accepted-for-review-by-the-european-medicines-agency-ema-for-the-treatment-of-adults-with-primary-hypercholesterolaemia-heterozygous-fa-302543737.html
18 Aug 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/08/18/3134956/0/en/NewAmsterdam-Announces-Acceptance-of-Marketing-Authorization-Applications-for-Review-by-European-Medicine-Agency-for-Obicetrapib.html
16 Dec 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/menarini-group-announces-positive-topline-data-from-pivotal-phase-3-broadway--tandem-clinical-trials-evaluating-obicetrapib-and-the-fixed-dose-combination-obicetrapib-with-ezetimibe-10-mg-302332562.html
11 Dec 2024
// FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/newamsterdam-shares-early-sign-cholesterol-drug-improves-cardiovascular-outcomes-sending
10 Dec 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/12/10/2994358/0/en/NewAmsterdam-Pharma-Announces-Positive-Topline-Data-from-Pivotal-Phase-3-BROADWAY-Clinical-Trial-Evaluating-Obicetrapib-in-Patients-with-Atherosclerotic-Cardiovascular-Disease-and-.html
Share 